KRYSTAL BIOTECH, INC.

(KRYS)
  Rapport
Vertraagde tijd Nasdaq  -  23/05 22:00:00 CEST
57.75 USD   -2.18%
09/05Krystal Biotech, Inc. Rapporteert Winstresultaten voor het Eerste Kwartaal Geëindigd 31 Maart, 2022
CI
11/04Krystal Biotech kondigt thuisdosering aan in B-Vec Open Label Verlengingsstudie
CI
29/03KRYSTAL BIOTECH, INC. : Guggenheim herhaalt koopadvies
MM
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproducten 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiŽle publicatiesSectornieuws
Nieuws in andere talen op KRYSTAL BIOTECH, INC.
23/05KRYSTAL BIOTECH, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
20/05KRYSTAL BIOTECH, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form ..
20/05Krystal Biotech to Present Additional Data on B-VEC from the GEM-3 Phase 3 Study at the..
10/05TRANSCRIPT : Krystal Biotech, Inc. Presents at Bank of America 2022 Healthcare Conference,..
09/05Earnings Flash (KRYS) KRYSTAL BIOTECH Reports Q1 Loss $-1.99
09/05Krystal Biotech Announces First Quarter 2022 Financial Results and Reports Updates on O..
09/05KRYSTAL BIOTECH, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND ..
09/05Krystal Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 20..
03/05Krystal Biotech to Participate in Bank of America Merrill Lynch Global Healthcare Confe..
11/04Krystal Biotech Plans Home-Dosing Option in Study of Investigational Skin Disorder Ther..
11/04Krystal Biotech Announces Home Dosing in B-VEC Open Label Extension Study
11/04Krystal Biotech Announces Home Dosing in B-Vec Open Label Extension Study
28/03KRYSTAL BIOTECH, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form ..
28/03Krystal Biotech Says Trial of Skin Disease Treatment Met Primary and Secondary Endpoint..
28/03Krystal Biotech Announces Publication of Phase 1 and 2 Clinical Trial (GEM 1/2 Study) o..
28/03Krystal Biotech Announces Publication of Phase 1 and 2 Clinical Trial (GEM 1/2 Study) o..
28/03TRANSCRIPT : Krystal Biotech, Inc. - Special Call
28/03Krystal Biotech, Inc. - New GEM-3 Phase 3 Results for B-VEC Presented at 2022 American ..
26/03New GEM-3 Phase 3 Results for B-VEC Presented at 2022 American Academy of Dermatology A..
26/03Krystal Biotech, Inc., Announces New GEM-3 Phase 3 Results for B-VEC Presented at 2022 ..
24/03Krystal Biotech to Participate in H.C. Wainwright and Guggenheim Investor Conferences
23/03Jeune Aesthetics Announces Positive Clinical Phase 1 (PEARL-1 Study) Efficacy Results f..
22/03KRYSTAL BIOTECH : Jeune Aesthetics Announces Positive Clinical Phase 1 (PEARL-1 Study) Eff..
22/03KRYSTAL BIOTECH, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form ..
22/03TRANSCRIPT : Jeune Aesthetics, Inc, Krystal Biotech, Inc. - Special Call
21/03Krystal Biotech to Present at 2022 American Academy of Dermatology Annual Meeting
18/03Krystal Biotech to Present at 2022 American Academy of Dermatology Annual Meeting
15/03KRYSTAL BIOTECH : Announces Settlement with PeriphaGen, Inc - Form 8-K
15/03KRYSTAL BIOTECH, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form ..
15/03Krystal Biotech Settles Litigation With PeriphaGen
15/03Krystal Biotech Announces Settlement with PeriphaGen, Inc.
01/03KRYSTAL BIOTECH : Reports Fourth Quarter and Full Year 2021 Financial Results and Provides..
28/02KRYSTAL BIOTECH, INC. : Results of Operations and Financial Condition, Change in Directors..
28/02Krystal Biotech, Inc. Announces Board Changes
28/02Krystal Biotech's Q4 Loss Widens
28/02KRYSTAL BIOTECH, INC. Management's Discussion and Analysis of Financial Condition and ..
28/02Krystal Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 202..
28/02Krystal Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Provide..
28/02NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
28/02Certain Restricted Stock Units of Krystal Biotech, Inc. are subject to a Lock-Up Agreem..
28/02Certain Stock Options of Krystal Biotech, Inc. are subject to a Lock-Up Agreement Endin..
28/02Certain Commom Stock of Krystal Biotech, Inc. are subject to a Lock-Up Agreement Ending..
24/02Krystal Biotech to Participate in Cowen's 42nd Annual Health Care Conference
18/01KRYSTAL BIOTECH : Appoints Jing Marantz, MD, PhD, MBA as Chief Business Officer and Rand S..
18/01KRYSTAL BIOTECH, INC. : Change in Directors or Principal Officers, Regulation FD Disclosur..
18/01Krystal Biotech Appoints Jing Marantz, MD, PhD, MBA as Chief Business Officer and Rand ..
18/01Krystal Biotech, Inc. Announces Management Changes
2021INSIDER SELL : Krystal Biotech
2021INSIDER SELL : Krystal Biotech
2021KRYSTAL BIOTECH, INC. : Entry into a Material Definitive Agreement, Financial Statements a..
2021Krystal Biotech Prices $200 Million Offering at $75/Share
2021Krystal Biotech Announces Pricing of $200 Million Public Offering of Common Stock
2021Krystal Biotech Starts $200 Million Share Sale
2021Krystal Biotech Announces Proposed $200 Million Public Offering of Common Stock
2021KRYSTAL BIOTECH : Announces Positive Topline Results from GEM-3 Pivotal Trial of VYJUVEK&#..
2021KRYSTAL BIOTECH, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form ..
2021Health Care Stocks Hanging On For Narrow Gains Near Monday Close
2021Krystal Biotech Genetic Skin Disorder Drug Trial Meets Primary Endpoint; Shares Rally
2021Health Care Stocks Rising Monday Afternoon
2021Top Midday Gainers
2021Wall Street Set for Rebound After Omicron-Induced Slump
2021Health Care Stocks Rally Premarket Monday
2021Health Care
2021Top Premarket Gainers
2021Krystal Biotech Soars Premarket as Genetic Skin Disorder Drug Trial Meets Primary Endpo..
2021TRANSCRIPT : Krystal Biotech, Inc. - Special Call
2021Krystal Biotech Shares More Than Double After Dystrophic EB Trial Meets Objectives
2021Krystal Biotech Announces Positive Topline Results from GEM-3 Pivotal Trial of†VYJUVEK&..
2021Krystal Biotech, Inc. Announces Positive Topline Results from GEM-3 Pivotal Trial of VY..
2021Krystal Biotech Reports Third Quarter 2021 Financial Results and Provides Update on Ope..
2021Krystal Biotech's Q3 Net Loss Widens
2021KRYSTAL BIOTECH, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND ..
2021Krystal Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months En..
2021Earnings Flash (KRYS) KRYSTAL BIOTECH Reports Q3 Loss $-0.70
2021Krystal Biotech Reports Third Quarter 2021 Financial Results and Provides Update on Ope..
1  2  3  4  5Volgende
Volgende evenement op KRYSTAL BIOTECH, INC.